We are proud to announce the successfull Marketing Authorization Application submission for our lead drug candidate, Xervyteg® (MaaT013) to the European Medicines Agency (EMA) for the treatment in adult patients with acute Graft-versus-Host Disease including gastro-intestinal involvement who received two prior lines of therapy.
